Johannes F.E. Mann, MD

Johannes F.E. Mann, MD
 

Professor of Medicine
University of Erlangen-Nürnberg
Director, Dept. of Nephrology, Hypertension & Rheumatology
Munich General Hospitals
Munich, Germany

What outcomes was the LEADER trial powered to assess? Can you specifically discuss the secondary microvascular outcomes in the kidney? Video

What outcomes was the LEADER trial powered to assess? Can you specifically discuss the secondary microvascular outcomes in the kidney?

What outcomes was the LEADER trial powered to assess? Can you specifically discuss the secondary microvascular outcomes in the kidney?
Johannes F.E. Mann, MD

Johannes F.E. Mann, MD

Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD? Video

Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD?

Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD?
Johannes F.E. Mann, MD

Johannes F.E. Mann, MD